insights_auto
Outlook: 76.9% bullish·0.0% bearish
Go to analysischevron_right
INO:NASDAQ
Inovio Pharmaceuticals Inc
1,92 $
arrow_upward
+1,58%(+0,030) 1D
3 қар., 10:45:22 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for INO...
Open
1,87 $
High
2,04 $
Low
1,60 $
Mkt. cap
198,51 млн
Avg. vol.
13,76 млн
Volume
20,46 млн
52-wk high
2,72 $
52-wk low
0,57 $
EPS
-1,17 $
Beta
1,71
Shares outstanding
103,40 млн
No. of employees
112
Open
1,87 $
High
2,04 $
Low
1,60 $
Mkt. cap
198,51 млн
Avg. vol.
13,76 млн
Volume
20,46 млн
52-wk high
2,72 $
52-wk low
0,57 $
EPS
-1,17 $
Beta
1,71
Shares outstanding
103,40 млн
No. of employees
112
News stories
From web sources and news partners
BioSpace
·
11 сағат бұрын
INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
News Corp
·
17 сағат бұрын
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Benzinga
·
18 сағат бұрын
12 Health Care Stocks Moving In Monday's After-Market Session
The Business Journals
·
21 сағат бұрын
Inovio sets price for its first FDA-approved drug at $115,000 per dose
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc